SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome p450 3a4. Curr Drug Metab 2008; 9: 31022.
  • 2
    Moore DD, Kato S, Xie W, Mangelsdorf DJ, Schmidt DR, Xiao R, Kliewer SA. International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol Rev 2006; 58: 74259.
  • 3
    Stanley LA, Horsburgh BC, Ross J, Scheer N, Wolf CR. PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. Drug Metab Rev 2006; 38: 51597.
  • 4
    Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 2001; 7: 58490.
  • 5
    Matic M, Mahns A, Tsoli M, Corradin A, Polly P, Robertson GR. Pregnane X receptor: promiscuous regulator of detoxification pathways. Int J Biochem Cell Biol 2007; 39: 47883.
  • 6
    Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Wrighton SA, Hancock M, Kim RB, Strom S, Thummel K, Russell CG, Hudson JR Jr, Schuetz EG, Boguski MS. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 2001; 11: 55572.
  • 7
    Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, Fuss C, Brehm I, Brinkmann U, Eichelbaum M, Wojnowski L, Burk O. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 2001; 29: 14549.
  • 8
    Koyano S, Kurose K, Saito Y, Ozawa S, Hasegawa R, Komamura K, Ueno K, Kamakura S, Kitakaze M, Nakajima T, Matsumoto K, Akasawa A, Saito H, Sawada J. Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region. Drug Metab Dispos 2004; 32: 14954.
  • 9
    Lim YP, Liu CH, Shyu LJ, Huang JD. Functional characterization of a novel polymorphism of pregnane X receptor, Q158K, in Chinese subjects. Pharmacogenet Genomics 2005; 15: 33741.
  • 10
    Wang XD, Li JL, Su QB, Deng XY, Lu Y, Chen J, Zhang JX, Zhao LZ, Zuo Z, Chan E, Chen X, Chowbay B, Xue CC, Huang M, Zhou SF. A pharmacogenetic study of pregnane X receptor (NR1I2) in Han Chinese. Curr Drug Metab 2007; 8: 77886.
  • 11
    Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 127194.
  • 12
    Mannel M. Drug interactions with St John's wort: mechanisms and clinical implications. Drug Saf 2004; 27: 77397.
  • 13
    Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, Weinryb I, Guida M, Hopkins PJ, Warner N, Hall J. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 1999; 66: 28894.
  • 14
    Funaki T, Soons PA, Guengerich FP, Breimer DD. In vivo oxidative cleavage of a pyridine-carboxylic acid ester metabolite of nifedipine. Biochem Pharmacol 1989; 38: 42136.
  • 15
    Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 17184.
  • 16
    Wang XD, Li JL, Lu Y, Chen X, Huang M, Chowbay B, Zhou SF. Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: application to a clinical herb–drug interaction study. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 852: 53444.
  • 17
    Balogh A, Gessinger S, Svarovsky U, Hippius M, Mellinger U, Klinger G, Hoffmann A, Oettel M. Can oral contraceptive steroids influence the elimination of nifedipine and its primary pyridine metabolite in humans? Eur J Clin Pharmacol 1998; 54: 72934.
  • 18
    Castaneda-Hernandez G, Hoyo-Vadillo C, Palma-Aguirre JA, Flores-Murrieta FJ. Pharmacokinetics of oral nifedipine in different populations. J Clin Pharmacol 1993; 33: 1405.
  • 19
    King CR, Xiao M, Yu J, Minton MR, Addleman NJ, Van Booven DJ, Kwok PY, McLeod HL, Marsh S. Identification of NR1I2 genetic variation using resequencing. Eur J Clin Pharmacol 2007; 63: 54754.
  • 20
    Zhou SF, Lai X. An update on clinical drug interactions with the herbal antidepressant St. John's wort. Curr Drug Metab 2008; 9: 394409.
  • 21
    Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 1999; 369: 1123.
  • 22
    Lanz RB, McKenna NJ, Onate SA, Albrecht U, Wong J, Tsai SY, Tsai MJ, O'Malley BW. A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 1999; 97: 1727.
  • 23
    Goodwin B, Hodgson E, Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 1999; 56: 132939.
  • 24
    Pascussi JM, Gerbal-Chaloin S, Duret C, Daujat-Chavanieu M, Vilarem MJ, Maurel P. The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu Rev Pharmacol Toxicol 2008; 48: 132.
  • 25
    Xie W, Radominska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES, Waxman DJ, Evans RM. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci USA 2001; 98: 337580.
  • 26
    Xie W, Barwick JL, Downes M, Blumberg B, Simon CM, Nelson MC, Neuschwander-Tetri BA, Brunt EM, Guzelian PS, Evans RM. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 2000; 406: 4359.